Previous 10 | Next 10 |
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that it has receive...
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the ...
Requisite clinical responses achieved in cohort 1 of Part A (1 st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 Recruitment of cohort 2 of Part A of TACTI-002, additional 19 patients, will begin shortly Recruitment of the first cohorts of parts B ...
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it will receive a mileston...
The Japanese Patent Office grants Immutep (NASDAQ: IMMP ) patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof”. More news on: Immutep Limited, Immutep Limited, Healthcare stocks news, Read more ...
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Pat...
SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new ...
SYDNEY, Australia, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the completion of its fully underwritten pro rata non-renounceable entitlement offer (“Entitlement Offer”)...
TACTI-002 patient recruitment update Three patients now enrolled and dosed in INSIGHT-004, recruitment ongoing Significant eftilagimod alpha clinical data expected in coming months: º AIPAC Phase II - first data expected in Q1 calendar year 2020 º TACTI-002 Phase II - fi...
Gainers: Camber Energy (NYSEMKT: CEI ) +107% . Acacia Communications (NASDAQ: ACIA ) +35% . Electrameccanica Vehicles (NASDAQ: SOLO ) +26% . Xenetic Biosciences (NASDAQ: XBIO ) +16% . iFresh Inc. (NASDAQ: IFMK ) +15% . Atreca (NASDAQ: BCEL ) +15% . Pareteum Corporation (NASDAQ:...
News, Short Squeeze, Breakout and More Instantly...
Media Release Final discussion with the FDA, successfully concluding the regulatory preparations for the TACTI-004 Phase III trial design to evaluate efti in combination with KEYTRUDA ® (pembrolizumab), MSD’s anti-PD-1 therapy, and standard chemotherapy in first-...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...